

History and Infrastructure of the Pediatric Emergency Care Applied Research Network (PECARN)

Rakesh D. Mistry, MD, MS

CHCO Section of Emergency Medicine

ACCORDS Learning Health Seminar

November 15, 2021



Children's Hospital Colorado
Section of Emergency Medicine



Disclosures

- Funding

Emergency Medical Services for Children Network for the sustainability of a Pediatric Emergency Care Applied Research Network. U03MC0007-11, Maternal Child Health Bureau

- No conflicts of interest



Objectives

1. Describe the infrastructure used to support the PECARN network and research studies
2. Identify challenges to conduct or large scale, multicenter prospective research in pediatric emergency medicine (PEM)
3. Describe the power and complexities of the PECARN Registry for large data research





What is PECARN?

- First federally-funded pediatric emergency medicine (PEM) research network in the US
- Goal: *Conduct meaningful and rigorous multi-institutional research into the prevention and management of acute illnesses and injuries in children and youth across the continuum of EM health care*
- Particularly useful to conduct studies in need of large sample sizes to analyze relatively rare outcomes



Why did we form PECARN?

- Prior multicenter network: Pediatric Emergency Medicine Collaborative Research Committee (1994)
 - Largely retrospective studies
 - No funding required
 - Open to many institutions
- Limitations
 - Fully dependent on volunteerism
 - Onerous regulatory management
 - No organized method for data management and analysis
 - Data issues: inadequate sample, case ascertainment, missingness





PECARN

- Federally-funded since 2001
 - HRSA/Maternal Child Health Bureau
 - Emergency Medical Services for Children (EMSC) program
 - Funds support infrastructure, **NOT** projects
- Infrastructure Composition (2001)
 - 6 Research Nodes: Pediatric and general EDs
 - Data Coordinating Center
 - Competitive renewal every 4 years




Current PECARN Organization


- 6 Research Node Centers
 - 18 hospital EDs
 - 6 Emergency Medical Service Affiliate agencies (1/node)
- 1 Prehospital node (3 EMS agencies)
- Data Coordinating Center (DCC, Univ of Utah)



PECARN Governance



PECARN: 2021



PECARN Node Example

- Pediatric EM Northeast, West, and South (PEM-NEWS)
 - Columbia/Morgan Stanley: Maria Kwok (Site PI)
 - Texas Children's Hospital: Andrea Cruz (Site PI)
 - Children's Hospital Colorado: Rakesh Mistry (Site PI)
 - Aurora Fire EMS Affiliate: Katheen Adelgais (EMSA PI)
- PEM-NEWS Nodal Administration
 - Peter Dayan (Primary Investigator)
 - Raquel Shrager (Nodal administrator)






PECARN Enrollment

- Prospective enrollment at each ED
 - Research Coordinator (1.0 FTE funded)
 - Additional RC or PRAs (Funded by each study)
- Data Coordinating Center
 - Centrally created IRB, consent, and data collection forms
 - Data management (OpenClinica and QueryManager)
 - Statistical analysis



DCC Faculty and Staff

- DCC PI: PECARN leadership and governance
- Project management (20)
- Data management/informatics (13)
- Biostatistics support (6 PhD/15 MS)
- IT systems (12)
- Manuscript development
- ***Concept-to-grant development process***



Submission of PECARN Studies

- Most originate within the existing EDs and EMSAs
- Non-PECARN investigators can submit with sponsorship from existing PECARN node
- Benefits
 - Access to over 1,000,000 ED visits per year
 - Scientific expertise
 - Data management and analysis via DCC
 - High extramural funding rate



Submission Process/Timelines



Submission Process/Timelines




Submission Process/Timelines


- Development within Node and Nodal Approval
- Concept submission/presentation to PECARN SC
 - Vote for acceptance
 - Feedback provided
- Protocol/Grant Submission
 - Subcommittee feedback
 - No vote
- Protocol/Grant Submission (for vote)
- PECARN Approval...*then* submit to funding agency



2001-Pres: Concepts, Protocols, Grants



PECARN Annual Funding



Foci of PECARN Research

Disease Processes

- Traumatic injuries
- Respiratory illnesses
- Infectious diseases
- Sickle cell anemia
- Adolescent & mental health
- Critical illnesses: sepsis, seizure, DKA
- Prehospital/EMS care

Methodologies

- Complex RCTs
- Prediction modeling
- Risk stratification
- ***Clinical decision support***
- ***Novel approaches to use of large data***



Foci of PECARN Research

Current Studies

Normal Saline vs. Lactated Ringers for Pediatric Sepsis

Azithromycin for Young Children with Wheezing

Dosing Regimen for Pediatric Seizures in the Prehospital Setting

Arginine for Sickle Cell Disease Vaso-Occlusive Crisis in Children

Procalcitonin to Determine Antibiotic Need in Children with Community-Acquired Pneumonia

Risk Stratification for Emergent Intracranial Abnormalities in Children with Headaches

Prediction Model for Pulmonary Embolus in Children

Risk Stratification for Pediatric Cervical Spine Injury

Pain Control in Children with Long Bone Fractures

Pediatric Sepsis Screening: Identification of Those at Risk




What about our patients?????



Pediatric Head Trauma

- 42,412 children enrolled
 - CT Scans: 14,969 (35.3%)
 - Clinically important TBI: 376 (0.9%)
- Rules derived for <2 and ≥ 2 yrs of age
- Negative Predictive Values
 - <2 yrs: 1176/1176 (100.0%; 99.7-100.0)
 - ≥ 2 yrs: 3798/3800 (99.95%; 99.81-99.99)



PECARN and Implementation Science

Use of Traumatic Brain Injury Prediction Rules With Clinical Decision Support

Peter S. Dayan, MD, MSc,^a Dustin W. Ballard, MD, MBE,^{b,c} Eric Tham, MD,^d Jeff M. Hoffman, MD,^e Marguerite Swietlik, MSN, RN,^f Sara J. Deakyne, MPH,^f Evaline A. Alessandrini, MD, MSCE,^g Leah Tzimenatos, MD,^{h,i} Lalit Bajaj, MD, MPH,^d David R. Vinson, MD,^{c,j} Dustin G. Mark, MD,^k Steve R. Offerman, MD,^l Uli K. Chettipally, MD, MPH,^m Marilyn D. Paterno, MSBI,ⁿ Molly H. Schaeffer, MSc,^o Jun Wang, MS,^p T. Charles Casper, PhD,^p Howard S. Goldberg, MD,^{n,o} Robert W. Grundmeier, MD,^q Nathan Kuppermann, MD, MPH,^{h,i} for the Pediatric Emergency Care Applied Research Network (PECARN), Clinical Research on Emergency Services and Treatment (CREST) Network, and Partners Healthcare; Traumatic Brain Injury-Knowledge Translation Study Group



PECARN Head Trauma: Bedside

PECARN Pediatric Head Injury/Trauma Algorithm ☆

Predicts need for brain imaging after pediatric head injury.

INSTRUCTIONS

Note: This only applies to children with **GCS** scores of 14 or greater.

When to Use ▾

Pearls/Pitfalls ▾

Why Use ▾

Age

<2 Years

≥2 Years

GCS ≤14, palpable skull fracture or signs of AMS

AMS: Agitation, somnolence, repetitive questioning, or slow response to verbal communication

No

Yes

Occipital, parietal or temporal scalp hematoma; history of LOC ≥5 sec; not acting normally per parent or severe mechanism of injury?

No

Yes

Severe mechanism: MVC with patient ejection, death of another passenger, rollover; pedestrian or bicyclist w/o helmet struck by motorized

Age

<2 Years

≥2 Years

GCS ≤14 or signs of basilar skull fracture or signs of AMS

AMS: Agitation, somnolence, repetitive questioning, or slow response to verbal communication

No

Yes

History of LOC or history of vomiting or severe headache or severe mechanism of injury

Motor vehicle crash with patient ejection, death of another passenger, or rollover; pedestrian or bicyclist without helmet struck by a motorized vehicle; falls of more than 1.5m/5ft; head struck by a high-impact object

No

Yes

PECARN recommends observation over imaging, depending on provider comfort; 0.9% risk of clinically important Traumatic Brain Injury.

Consider the following when making imaging decisions: Physician experience, worsening signs/symptoms during observation period, age <3 months, parent preference, multiple vs. isolated findings: patients with certain isolated findings (i.e., no other findings suggestive of TBI), such as isolated LOC, isolated headache, isolated vomiting, and certain types of isolated scalp hematomas in infants >3 months have ciTBI risk substantially <1%.

Copy Results 📄

Next Steps >>>

Decision Aid 🧠





CALIFORNIA ACEP
AMERICAN COLLEGE OF EMERGENCY PHYSICIANS


A California ACEP/Choosing Wisely Collaboration



Pediatric Head Trauma CT Decision Guide

Children 2 years and older

**2 YEARS
& OLDER**




*ci-TBI: risk of clinically important TBI needing acute intervention, based on PECARN validated prediction rules



Application in Practice

Reduction of Computed Tomography Use for Pediatric Closed Head Injury Evaluation at a Non-pediatric Community Emergency Department



Ballard DW, Pediatric Emergency Care Applied Research Network (PECARN);. Ann Emerg Med. 2019 May;73(5):440-451.




Upcoming Development of CDS

- Implementation of ED-based Antimicrobial Stewardship (PI: Mistry)
- Implementation of Febrile Infant Clinical Decision Rule (PIs: Mahajan/Kuppermann)

The screenshot shows the Epic EMR interface for a patient named Henrietta Rakeshtest. The main window is titled "Dispo" (Disposition). On the left, there is a patient information sidebar including name, age (4 years old), sex (Female), MRN (2360419), and vital signs. The main area shows a search for "UTI" with a "Suggested by Chief Complaint" section indicating no suggestions. Below this is a "SmartSets/OrderSets" section with checkboxes for various disposition codes like "CPT New Patient", "DC COVID-19 (Dispo)", "DC Dispo Orders (Dispo)", "DC Generic Discharge (Dispo)", "DC Urinary Tract Infection (UTI) - UPDATED - (Dispo)", "ED Admit (Dispo)", and "ED Transfer (Dispo)". On the right, there is a "BestPractice Advisories" section for "Urinary Tract Infection" with detailed clinical guidance, including antibiotic therapy choices (Cephalexin, PCN Allergic: Trimethoprim-Sulfamethoxazole) and duration of treatment (Cystitis: 3 days, Pyelonephritis: 10 days).



Datasets and Big Data



PECARN Public Use Datasets

- Federally-funded data released 3 years after lock
- Complete, de-identified study data available
- Currently 15 datasets available for use

THE EFFECTIVENESS OF ORAL DEXAMETHASONE FOR ACUTE BRONCHIOLITIS: A MULTICENTER RANDOMIZED CONTROLLED TRIAL

Study Period: January 2004 - April 2006
Study Type: Interventional
Study Enrollment: 598
Consent: Yes

PURPOSE

This study compared a single dose of oral dexamethasone to placebo in a multicenter, randomized, double blind trial of infants aged 2 to 12 months with first-time bronchiolitis (defined as wheezing within 7 days of onset). This is given as additional therapy beyond any other routine therapy used at that center. No current standard therapy is withheld, and no additional tests or other treatments are part of the study. The primary hypothesis was that dexamethasone would be more effective than placebo in preventing hospital admission. The secondary hypotheses were that dexamethasone would decrease respiratory scores and possibly the duration of the disease when compared to placebo, and that dexamethasone would be as safe and as well tolerated as placebo.

Data Dictionary (PDF)
Data Forms (PDF)
Protocol (PDF)
Primary Manuscript (URL)
Download Data

<https://pecarn.org/datasets/>



PECARN Registry Project

- Funded by AHRQ in 2012
- Objective: Create medical record registry via compete EHR data extraction from multiple sites
- Potential Uses
 - Grant preparation and future research
 - Quality improvement
 - Funded research
 - Predictive modeling, risk assessment, machine learning
 - Comparative effectiveness
 - Linked for prospective enrollment



PECARN Registry

- Participating EDs
 - Initially 4 sites; now 12
 - 10 Epic EHR and 2 Cerner
- Complete EHR ED visits
- Transfers monthly to DCC

**Cumulative Totals
2012-2020**

Data point	Total
Sites	12
Encounters	5,184,410
Patients	1,918,346
Diagnoses	21,843,323
Lab Tests	5,272,065
Lab Results	38,621,682
Microbiology Tests	2,184,617
Microbiology Results	2,842,939
Medication Orders	7,294,339
Medication Administrations	7,959,884
Radiology Tests	1,990,308
Narrative Documents	28,105,263
Providers included in report cards	1,643



PECARN Registry Variables

- Patient Identifiers: Patient number, encounter number
- Demographics: Date of birth (DOB), sex, race, ethnicity, zip, payer
- Visit Information: Triage category, chief complaint, arrival mode
- Date/Time: notification, ED door, sort/triage, discharge
- Providers: Provider ID, provider role, provider D/T
- Vitals: Vitals D/T, T, HR, RR, SBP, DBP, oxygen saturation, weight
- Medications: Current; ED (D/T); discharge
- Clinical Assessments: Asthma score, Pain score, Glasgow Coma Scale (GCS)
- **Narrative: Narrative D/T, author type, narrative**
- Radiology: Order D/T, start D/T, avail D/T, report D/T, report
- Labs (including Micro): Lab D/T result
- Procedures: CPT, ICD9, ICD10
- Diagnosis: ICD9, e-codes, ICD10
- Disposition: ED disposition, Hospital discharge D/T, Vital status




PECARN Registry: Data Flow



Bringing Registry Data to the Provider



- Automated feedback
 - Associated with improvements in care
 - Assists with sustainability of change
- Report cards



Monthly Site Report Cards



Systemic corticosteroids given in the ED

Site	92.3% (N=52)
Network	92.2%
ABC	98.3%





Time (min) to first beta-agonist treatment

Site (med[IQR])	44 [30,60] (N=52)
Network (med[IQR])	46 [29,72]
ABC	27



Asthma score documented while in the ED

Site	78.8% (N=52)
Network	90.6%
ABC	100%




Semi-annual Provider Report Card

Respiratory Diseases (Asthma): *All Respiratory Diseases performance measures include only visits of patients ≥ 2 years of age with an asthma diagnosis and 2 or more doses of beta-agonist (based on weight) given in the ED (regardless of disposition except where noted)*



Systemic corticosteroids given in the ED

You	90% (N=30)
Your Site	87.3%
Network	89.2%
Site ABC	98.2%
Network ABC	98.5%





Time (min) to first beta-agonist treatment

You (med[IQR])	72 [37,111] (N=30)
Your Site (med[IQR])	53 [29,108]
Network (med[IQR])	50 [29,87]
Site ABC	28
Network ABC	27



PECARN Registry: Process



PECARN Registry Funding

- AHRQ Funded 2011-2015
- Current Ongoing Funding
 - Data Coordinating Center
 - Project funding
 - Participating sites: Annual fee
- Project specific grant funding
 - Validation of new variables
 - Data management
 - Statistical analysis



PECARN Registry Related/Linked Studies

PED Screen

R01HD087363 (Elizabeth Alpern)

- Pediatric Sepsis EHR Registry, Clinical Outcomes, and Predictive Model Research Strategy.
- This study will create a multi-centered pediatric emergency care sepsis registry derived from EHR data, develop and validate methods to identify children at risk of severe sepsis, and develop predictive model to identify patients at risk of developing sepsis.

IMPROVE

R01HD091302 (Amy Drendel)

- The Effect of Emergency Department and After-Emergency Department Analgesic Treatment on Pediatric Long Bone Fracture Outcomes.
- The overall goal is to evaluate and provide evidence for both ED and post-ED pain treatment for all children with acute fracture-related pain. Uniquely, this study prospectively tracks the full patient experience from ED visit to home.

SCIENCE

U01HL143477 (David Brousseau)

- Implementation of evidence-based care for the acute treatment of sickle cell disease pain.
- Identify the barriers and facilitators to NHLBI guideline adherent care for pain in SCD, allowing for successful design of a multi-center hybrid 3 implementation trial to improve the experience of children with SCD presenting in acute pain.

Disparities in ED Care

R03MD011654 (Monika Goyal)

- Detecting Racial and Ethnic Disparities in Pediatric Emergency Care Using the PECARN Data Registry
- detect and document racial and ethnic disparities in the management of acute pain among children presenting to emergency departments (ED) with long bone fractures and those diagnosed with appendicitis.



Thank you!!!!

- Acknowledgments

Elizabeth R. Alpern, MD, MSCE

Peter S. Dayan, MD, MSc

- CHCO PECARN Colleagues

Lalit Bajaj, MD, MPH

Sara Deakyne

Kathleen Adelgais, MD, MPH

Jennifer Sadlowski

Gonzalo Lerner

Kathleen Grice

Mimi Munroe





Children's Hospital Colorado
Section of Emergency Medicine



Pediatric Emergency Research Networks

- Global network of networks
- 8 member PEM networks
- Studies
 - H1N1 pandemic
 - Practice patterns
 - COVID-19 pandemic





UTI CDS Appearance



UTI CDS

Citrix Viewer View Devices
Hyperspace - SUBJECT MATTER EXPERT - URGENT/EMER CARE-SOUTH - RAKESH I | 1: Chart Completion | 11: Incomplete Notes | Thu Jul 15 1:04 PM

Epic Chart ED Track Board ED Chart ED Manager ED Map My Reports Calculator Remind Me Census Snapshot Report

Rakeshtest, Henrietta | SUBJECT MATTER EXPERT RAKESH D MISTRY ASAP

Dispo

SmartSet Help Text Care Teams PCP/Ref Notify

Impressions

Add a new impression + Add

Suggested by Chief Complaint
No suggestions to display

Impressions
No impressions to display

SmartSets/OrderSets

Add a SmartSet + Add

- DC COVID-19 (Dispo)
- DC Dispo Orders (Dispo)
- DC Generic Discharge (Dispo)
- ED Admit (Dispo)
- ED Transfer (Dispo)

BestPractice Advisories
No advisories to address.

Henrietta Rakeshtest
Female, 4 year old 8 month old, 10/18/2016
MRN: 2360419
Total Time: 6215:23
Code: Not on file (no ACP docs)
None

No assigned RN
COVID-19 Vaccine: Unknown
COVID-19: Unknown
IC Alert: None

ALLERGIES
No Known Allergies

PROBLEM LIST (0)

CHIEF COMPLAINT
Painful Urination
Wt: 15.4 kg
Dose Wt: 15.4 kg
Temp: 37.7 °C (99.9 °F) > 1 day
Temp Source: TYMPANIC > 1 day
Pulse: 108 > 1 day
BP: 101/71 > 1 day
SpO2: 100% > 1 day

When you enter the impression the CDS "activates"

In the background, when a UA is ordered, the CDS is triggered for activation, but you will not know



UTI CDS

Broad impressions will activate (e.g. UTI, Pyelo, Cystitis)

New CDS orderset populates

BPA box with guideline info and active links if desired

The screenshot displays the Epic EMR interface for a patient named Henrietta Rakeshtest. The patient's demographic information and vital signs are visible on the left. The main chart area shows a 'Dispo' (Disposition) screen with a search for 'UTI'. Under 'Impressions', 'Urinary tract infection' is listed. Below this, the 'SmartSets/OrderSets' section is highlighted, showing a list of ordersets including 'DC Urinary Tract Infection (UTI) - UPDATED - (Dispo)'. On the right side, a 'Best Practice Advisory' (BPA) box is open, titled 'Urinary Tract Infection'. The BPA provides clinical guidance, including antibiotic therapy choices (Cephalexin, Trimethoprim-Sulfamethoxazole) and duration of treatment (3 days for Cystitis, 10 days for Pyelonephritis). It also includes links to clinical pathways and guidelines.



UTI CDS

Dispo

Henrietta Rakeshtest
Female, 4 year old 8 month old, 10/18/2016
MRN: 2360419
Total Time: 6215:25

Dispo Orders

- DC COVID-19 (Dispo)
- DC Dispo Orders (Dispo)
- DC Generic Discharge (Dispo)
- DC Urinary Tract Infection (UTI) - UPDATED - (Dispo)
- ED Admit (Dispo)
- ED Transfer (Dispo)

SmartSet Procedures

Suggested by SmartSets

Order ED Lab Follow-up IB Message

Prescriptions & Orders

Suggested by SmartSets

- Order cephalexin (KEFLEX) 250 MG/5ML Reconstituted Suspension
- Order cephalexin (KEFLEX) 500 MG Cap

Discharge Education

Secure AVS

URINARY TRACT INFECTION

- This patient has been diagnosed with a Urinary Tract Infection (UTI) such as cystitis or pyelonephritis
- Antibiotic Therapy choices at CHCO
 - First-line: Cephalexin
 - Second-line (PCN Allergic): Trimethoprim-Sulfamethoxazole
 - Duration of treatment
 - Cystitis: 3 days
 - Pyelonephritis: 10 days
- Antibiotic recommendations and duration of therapy provided are based on the sources linked below:
 - CHCO UTI Clinical Pathway (updated 9/2019)

New Discharge Orders

cephalexin (KEFLEX) 250 MG/5ML Reconstituted Suspension
385 mg (7.7 mL) by mouth four times a day for 3 days, Disp-92.4 mL, R-0, No

E-prescribing error. Click Details.
Invalid items: Pharmacy

Sign

When orderset checked, only correct choice displayed

“Correct” choices based on patient age, presence of allergy, and presence of fever

Antibiotic prescription fully prepopulated for dose and duration. You only need to “sign”!!!!

UTI CDS

Citrix Viewer View Devices Thu Jul 15 1:08 PM

Epic Hyperspace - SUBJECT MATTER EXPERT - URGENT/EMER CARE SOUTH - RAKESH D MISTRY | 1 - Chart Completion | 11 - Incomplete Notes

cephalexin (KEFLEX) 250 MG/5ML Recon Susp

Reference: 1. CHCO Formulary

Note to Pharmacy: + Add Note to Pharmacy (F6)

Recommended dose: This patient has had a prior UTI -- Base treatment on prior antibiotic sensitivities if possible.
25 mg/kg/dose (max: 500 mg/dose) PO four times per day for 3 days

Product: **CEPHALEXIN 250 MG/5ML PO RECON SUSP**

Sig Method: Specify Dose, Route, Frequency | Use Free Text | Taper/Ramp | Combination Dosage

Dose: 25 mg/kg/dose | 12.5 mg/kg/dose | **25 mg/kg/dose** | 37.5 mg/kg/dose

Weight Type: Recorded | **Dosing** | Order-Specific

Weight: 15.4 kg | 15.4 kg

Dosing weight: 15.4 kg (recorded 249 days 11 hours ago)

Prescribed Dose: 385 mg

Prescribed Amount: 7.7 mL

Route: Oral | **Oral** | Nasogastric | Gastrostomy Tube | Orogastric | J-Tube | Transpyloric | G-J Tube | Oral/NG-Tube | Oral/G-tube

Frequency: FOUR TIMES A DAY | **QID** | Q6H | TID | BID

Duration: 3 | Doses | **Days** | 3 days | 7 days | 10 days | 14 days

Starting: 7/15/2021 | Ending: 7/18/2021

Dispense: 92.4 mL | Refill: 0 | 0 | 1 | 2 | 3 | 5 | 11

Total Supply: 3 Days

Do not send renewal requests to me

Dispense As Written

Mark long-term: CEPHALEXIN

E-prescribing error. Click Details.
Invalid Items: Pharmacy

Rx: UNKNOWN

Buttons: Accept, Cancel, Remove All, Sign

No need to open prescription, but this is how it appears with pre-populated data




Project Wins:



Technology has been developed to extract data for all emergency department visits, accomplish substantial de-identification of the extract prior to transmission to the Data Coordinating Center (DCC), and produce a data warehouse registry to use for quality improvement and research.



Quality Assurance: Comprehensive data quality assurance rules are automated to assess data quality and validation of the transmitted data. Monthly data quality reports are constructed for each site by month and entire year data breakdown to facilitate effective and efficient data quality review.



Report Cards: Data from the Registry is used to assess stakeholder prioritized quality of care performance measures and determine benchmarks for the metrics. Site-level report cards are populated from the Registry and distributed monthly and semi-annually. Provider-level report cards are distributed semi-annually.

Benefits:

- Captures ALL patients to ED
- Captures wide range of data (EHR reality; includes text)
- ED specific data (lacking in many other sources)
- Allows for organization of data to facilitate analysis
- Allows for ongoing temporal collection of data leading to responsive analysis (Network-level, Site-level)
- Allows for active linkage for prospective studies
- Innovative grants with proven success
- Scalable (3 waves of entry) and maintainable (reasonable IT effort)

Challenges:

- EHRs are ever-changing
- Each new site that joins is going to have a new challenge or identify a problem that every prior site missed
- Site ongoing IT collaboration
- Consistence of staffing over time